Future of antiarrhythmic drugs

Current Opinion in Cardiology

Volumn 21, Issue 4, 2006, Pages 361-367

  Darbar, Dawood ^a   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Ion channels; Ventricular fibrillation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL T TYPE; SOTALOL;

CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; HEART ARRHYTHMIA; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; DRUG DESIGN; HEART CONDUCTION SYSTEM; HUMANS; ION CHANNELS; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 33748176843     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000231407.61683.05     Document Type: Review

References (59)

1. Vaughan Williams EM. The experimental basis for the choice of an antiarrhythmic drug. Adv Cardiol 1970; 4:275-289.
2. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81:299-307.
3. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998; 98:2334-2351.
4. Weiss JN, Chen PS, Qu Z, et al. Ventricular fibrillation: how do we stop the waves from breaking? Circ Res 2000; 87:1103-1107.
5. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788.
6. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7-12.
7. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857-865.
8. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349:667-674.
9. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675-682.
10. Friedman LM, Byington RP, Capone RJ, et al. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 1986; 67:1-8.
11. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990; 66:779-785.
12. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319:385-392.
13. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341:1447-1457.
14. Hondeghem LM. Antiarrhythmic agents: modulated receptor applications. Circulation 1987; 75:514-520.
15. Ranger S, Talajic M, Lemery R, et al. Amplification of flecainide-induced ventricular conduction slowing by exercise: a potentially significant clinical consequence of use-dependent sodium channel blockade. Circulation 1989; 79:1000-1006.
16. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350:1013-1022.
17. Benz I, Kohlhardt M. Responsiveness of cardiac Na+ channels to antiarrhythmic drugs: the role of inactivation. J Membr Biol 1991; 122:267-278.
18. Benz I, Kohlhardt M. Chemically modified cardiac Na+ channels and their sensitivity to antiarrhythmics: is there a hidden drug receptor? J Membr Biol 1994; 139:191-201.
19. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12:17-23.
20. Splawski I, Tristani-Firouzi M, Lehmann MH, et al. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 1997; 17:338-340.
21. Splawski I, Timothy KW, Vincent GM, et al. Molecular basis of the long-QT syndrome associated with deafness. N Engl J Med 1997; 336:1562-1567.
22. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1. LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000; 35:778-786.
23. Swartz KJ, MacKinnon R. Hanatoxin modifies the gating of a voltage-dependent K+ channel through multiple binding sites. Neuron 1997; 18:665-673.
24. Wang J, Salata JJ, Bennett PB. Saxitoxin is a gating modifier of HERG K+ channels. J Gen Physiol 2003; 121:583-598.
25. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995; 92:1954-1968.
26. Fareh S, Benardeau A, Nattel S. Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res 2001; 49:762-770.
27. Ohashi N, Mitamura H, Tanimoto K, et al. A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling. J Cardiovasc Pharmacol 2004; 44:386-392.
28. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003;107:1440-1446.
29. Doerr T, Denger R, Doerr A, Trautwein W. Ionic currents contributing to the action potential in single ventricular myocytes of the guinea pig studied with action potential clamp. Pflugers Arch 1990; 416:230-237.
30. Bohn G, Moosmang S, Conrad H, et al. Expression of T- and L-type calcium channel mRNA in murine sinoatrial node. FEBS Lett 2000; 481:73-76.
31. Mishra SK, Hermsmeyer K. Inhibition of signal Ca2+ in dog coronary arterial vascular muscle cells by Ro 40-5967. J Cardiovasc Pharmacol 1994; 24:1-7.
32. Mishra SK, Hermsmeyer K. Selective inhibition of T-type Ca2+ channels by Ro 40-5967. Circ Res 1994; 75:144-148.
33. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103:196-200.
34. Fozzard HA. Afterdepolarizations and triggered activity. Basic Res Cardiol 1992; 87:105-113.
35. Marban E, Robinson SW, Wier WG. Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle. J Clin Invest 1986; 78:1185-1192.
36. Priori SG, Corr PB. Mechanisms underlying early and delayed afterdepolarizations induced by catecholamines. Am J Physiol 1990; 258:H1796-H1805.
37. Volders PG, Kulcsar A, Vos MA, et al. Similarities between early and delayed afterdepolarizations induced by isoproterenol in canine ventricular myocytes. Cardiovasc Res 1997; 34:348-359.
38. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995; 123:358-367.
39. Anderson ME, Braun AP, Wu Y, et al. KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. J Pharmacol Exp Ther 1998; 287:996-1006.
40. Zhang R, Khoo MS, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 2005; 11:409-417. This is the first study that has provided a tenable link between excitation and contraction coupling in the heart. The authors demonstrated that inhibition of CaMKII prevented hypertrophy, arrhythmias, and sudden death in a mouse model. The findings of this study provide a novel approach for developing new antiarrhythmic drugs targeting molecules such as CaMKII.
41. Anderson ME. Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther 2005; 106:39-55. An excellent and comprehensive review on how modulation of CaMK may provide a new therapeutic strategy for the development of antiarrhythmic drugs.
42. Wehrens XH, Lehnart SE, Huang F, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003; 113:829-840.
43. Gaburjakova M, Gaburjakova J, Reiken S, et al. FKBP12 binding modulates ryanodine receptor channel gating. J Biol Chem 2001; 276:16931-16935.
44. Wehrens XH, Lehnart SE, Reiken SR, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 2004; 304:292-296.
45. Feng J, Wible B, Li GR, et al. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ Res 1997; 80:572-579.
46. Knobloch K, Brendel J, Peukert S, et al. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naunyn Schmiedebergs Arch Pharmacol 2002; 366:482-487.
47. Blaauw Y, Gogelein H, Tieleman RG, et al. 'Early' class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004; 110:1717-1724.
48. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897-1903.
49. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
50. Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42:81-87.
51. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
52. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104:2886-2891.
53. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89:E32-E38.
54. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104:174-180.
55. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004; 110:368-373.
56. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376-380.
57. L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44:159-164.
58. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106:331-336.
59. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45:1832-1839. This meta-analysis of 11 randomized studies involving 56 308 patients suggests that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers markedly reduce the risk of developing atrial fibrillation, though the benefit appears to be limited to patients with systolic left ventricular dysfunction or left ventricular hypertrophy.